New CAR-T therapy aims to tackle tough blood cancers

NCT ID NCT07200479

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 33 times

Summary

This early-stage study tests a new treatment called CT1194D CAR-T cells for patients whose B-cell blood cancers have returned or not responded to standard therapy. The main goals are to check the treatment's safety and find the best dose. About 20 adults aged 18-75 will take part, and researchers will also monitor how well the cancer responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • China Institute of Hematology and Blood Diseases Hospital

    Tianjin, 301617, China

  • China Institute of Hematology and Blood Diseases Hospital

    Tianjin, 301617, China

  • China Institute of Hematology and Blood Diseases Hospital

    Tianjin, 301617, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.